- Home
- RWAY vs MAZE Comparison
RWAY vs MAZE Comparison
Compare RWAY & MAZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RWAY
- MAZE
- Stock Information
- Founded
- RWAY 2015
- MAZE 2018
- Country
- RWAY United States
- MAZE United States
- Employees
- RWAY N/A
- MAZE N/A
- Industry
- RWAY
- MAZE
- Sector
- RWAY
- MAZE
- Exchange
- RWAY Nasdaq
- MAZE NYSE
- Market Cap
- RWAY 395.5M
- MAZE 367.0M
- IPO Year
- RWAY 2021
- MAZE 2025
- Fundamental
- Price
- RWAY $10.04
- MAZE $9.86
- Analyst Decision
- RWAY Buy
- MAZE Strong Buy
- Analyst Count
- RWAY 7
- MAZE 3
- Target Price
- RWAY $11.07
- MAZE $25.67
- AVG Volume (30 Days)
- RWAY 308.7K
- MAZE 199.0K
- Earning Date
- RWAY 05-12-2025
- MAZE 01-01-0001
- Dividend Yield
- RWAY 12.06%
- MAZE N/A
- EPS Growth
- RWAY 73.09
- MAZE N/A
- EPS
- RWAY 1.66
- MAZE 1.25
- Revenue
- RWAY $140,021,000.00
- MAZE $167,500,000.00
- Revenue This Year
- RWAY N/A
- MAZE N/A
- Revenue Next Year
- RWAY $0.71
- MAZE N/A
- P/E Ratio
- RWAY $6.03
- MAZE $7.86
- Revenue Growth
- RWAY N/A
- MAZE N/A
- 52 Week Low
- RWAY $8.35
- MAZE $6.71
- 52 Week High
- RWAY $12.21
- MAZE $17.00
- Technical
- Relative Strength Index (RSI)
- RWAY 62.20
- MAZE N/A
- Support Level
- RWAY $8.95
- MAZE N/A
- Resistance Level
- RWAY $9.25
- MAZE N/A
- Average True Range (ATR)
- RWAY 0.23
- MAZE 0.00
- MACD
- RWAY 0.13
- MAZE 0.00
- Stochastic Oscillator
- RWAY 83.33
- MAZE 0.00
About RWAY Runway Growth Finance Corp.
Runway Growth Finance Corp is a specialty finance company focused on providing senior secured loans to high-growth-potential companies in technology, life sciences, healthcare information and services, business services, select consumer services and products, and other high-growth industries. The company has Investments in the United States, Germany, and Canada, with the majority of its portfolio invested in the United States.
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.